References
- Hann I M, Stevens R F, Goldstone A H, Rees J K, Wheatley K, Gray R G, Burnett A K. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML Trial (MRC AML 10). Blood 1997; 89: 2311–2318
- Goldstone A H, Burnett A K, Wheatley K, Smith A G, Hutchinson R M, Clark R E. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311
- Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML: 10 Trial. Blood 1998; 92: 2322–2333
- Gale R E, Hills R, Kottaridis P D, Srirangan S, Wheatley K, Burnett A K, Linch D C. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005; 106: 3658–3665
- Kottaridis P D, Gale R E, Frew M E, Harrison G, Langabeer S, Belton A A, Walker H, Wheatley K, Bowen D T, Burnett A K, Goldstone A H, Linch D C. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 Trials. Blood 2001; 98: 1752–1759
- Burnett A K, Goldstone A H, Stevens R, Hann I M, Rees J K, Gray R G, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation in intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 Trial. Lancet 1998; 351: 700–708
- Burnett A K, Wheatley K, Goldstone A H, Stevens R F, Hann I M, Rees J KH, Harrison G. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML10 Trial. Br J Haematol 2002; 118: 385–400
- Burnett A K, Milligan D, Prentice A G, Goldstone A H, McMullin M F, Hills R K, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114–1124